Drug Delivery Technologies

(Image: Getty/Shidlovski)

Genentech taps Halozyme’s tech in Herceptin Hylecta

By Maggie Lynch

Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.

Delays, good sometimes

Novozymes' HA Delays API Release and Boosts Drug Half-Life

By Gareth Macdonald

Delays are annoying. Whether you are a journalist trying to ask a few quick questions without involving teams of public relations people or a driver stuck in a traffic jam, delays are normally a bad thing.